COVID-19 | POSITIVE IMPACT ON BIOTECH/BIOPHARMA INDUSTRIES

For clarification, I’m not happy with the massive loss of loved ones nor the ongoing global economic downturn caused by COVID-19. I’m simply pointing out the “bit of light” that the COVID-19 Pandemic is shining on the biotechnology/biopharmaceutical industries, including the positive economic upturn it provides for both employers and their current/future employees.

The COVID-19 Pandemic unfortunately & fortunately brings nothing but a positive impact to the biotech/biopharma financial “bottom-line”. Traditionally, the biotechnology / biopharmaceutical companies are the primary defense to maintain the “Good Health” status within both human & animal populations. However, during times of health pandemics, biotech/biopharma companies are forced to collaborate in order to rapidly produce the appropriate treatment to slow the progression of an illness as well as eradicate it to undetectable levels for the sake of the Human Race (including animals, i.e. Food Supply).

These actions will cause a “domino effect” in regard to opportunities for biotech/biopharma companies to increase market share, increase gross revenue, and create new points of market entry for companies with:

• Availability of Services to support the Biological War against COVID-19
• New/Advanced Technological Capabilities, including intellectual property (IP)
• Unique Foundation of Knowledge
• Bioprocessing Capacity

Due to the global focus on the development/production of a therapeutic treatment for COVID-19, the following events will ensue:

Simultaneously, Biotechnology Companies, including CDMOs, CMOs & CROs, with significant manufacturing capacity as well as diagnostic tools & analytical capabilities will increase their gross revenue due to:

There will be an increase in demand for commercial real estate in order to increase capacity for Wet Lab Facilities, Small Scale Bioprocessing Facilities, Large-Scale Bioprocessing Facilities and Manufacturing Facilities for PPE / Sanitation Products, i.e. N95 Face-Masks & Hand-Sanitizer. Due to Social Distancing & increased #s for our U.S. Remote Workforce, companies in the market for commercial real estate will have the advantage with regards to price negotiations, favorable terms for loans, interest rates, and alternative finance methods, i.e. venture capital and/or private investment.

More importantly, due to COVID-19, the U.S. Biotech/Biopharma Workforce will transform to one that is inclusive of both digitization as well as laborers that are willing to be trained on new/advanced technology & software applications. Hopefully, it will promote a biotech/biopharma workforce that illustrates real-world inclusivity, diversity & equality.

Additional Sources for this Topic: MarketWatch